Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00767520
• Other study ID #: CA180-261
• Status: Completed
• Phase: Phase 2
• First received: October 6, 2008
• Last updated: February 22, 2013
• Start date: February 2009
• Est. completion date: December 2012

Study information

• Verified date: July 2012
• Source: Bristol-Myers Squibb
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a non-steroidal aromatase inhibitor (NSAI).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 155
• Est. completion date: December 2012
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically-documented invasive estrogen receptor positive breast cancer , with tumor tissue from prior surgery available for analysis

• Prior therapy with a non-steroidal aromatase inhibitor

• Recurrent or progressive advanced breast cancer (locally-advanced or metastatic)

• Documented breast cancer with tumor = 28 days prior to study entry

• Women who are NOT of childbearing potential

• Must be able to take oral medication

• Performance Status 0 or 1

Exclusion Criteria:

• Pleural or pericardial effusion or ascites (of any etiology; Grade = 1) within 6 months prior to study entry

• Any chemotherapy, immunotherapy < 6 months before study entry. Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI

• Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry

• Prior exposure to exemestane, any Src-family kinase inhibitor including dasatinib, to agents intended to control osteolytic disease other than bisphosphonates, or to any investigational agent for breast cancer

• Concurrent or previous malignant disease requiring chemotherapy or radiation treatment within the prior 3 years

• Significant bleeding disorder, or ongoing or recent clinically-significant gastrointestinal bleeding

• Any serious cardiac condition, including congestive heart failure or myocardial infarction within 6 months, uncontrolled angina, or Class III or IV heart disease as defined by the New York Heart Association, baseline ejection fraction = 40%, diagnosed congenital long QT syndrome, clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), QTc interval > 450 msec at baseline (Fridericia correction)

• Hematologic abnormality Grade = 2

• Hypocalcemia of Grade = 1

• Any Chemistry abnormality of Grade = 2 [except Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease]

• Pregnant Women and Women of Childbearing Potential (WOCBP)

• Extremely lactose intolerant, in the judgment of treating physician (100 mg dasatinib contains 135 mg lactose, posing a problem only if intolerance is severe)

• Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Subjects must discontinue drug use at least 7 days prior to starting dasatinib)

• Potent inhibitors of CYP3A4 isoenzyme

• Prisoners or subjects who are involuntarily incarcerated; or subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Exemestane + Dasatinib
Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
• Exemestane + Placebo
Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity

Locations

Country	Name	City	State
Czech Republic	Local Institution	Hradec Kralove
Czech Republic	Local Institution	Prague 5
France	Local Institution	Lille
France	Local Institution	Paris Cedex 13
France	Local Institution	Saint-Cloud Cedex
Ireland	Local Institution	Dublin
Poland	Local Institution	Gdansk
Poland	Local Institution	Gdansk
Poland	Local Institution	Lodz
Poland	Local Institution	Opole
Spain	Local Institution	Madrid
Spain	Local Institution	Madrid
Spain	Local Institution	Torrevieja
Sweden	Local Institution	Vasteras
United Kingdom	Local Institution	Chelmsford	Essex
United Kingdom	Local Institution	Coventry	Warwickshire
United Kingdom	Local Institution	London	Greater London
United States	Compassionate Cancer Care Medical Group, Inc	Fountain Valley	California
United States	The West Clinic	Memphis	Tennessee
United States	Pennsylvania Oncology/Hematology Associates	Philadelphia	Pennsylvania
United States	Compassionate Cancer Care Medical Group Inc	Riverside	California

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Czech Republic,  France,  Ireland,  Poland,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS) Distribution for Exemestane Plus Dasatinib vs Exemestane Plus Placebo	PFS= The time (weeks) from date of randomization to date of progressive disease(PD). PFS for each randomization arm was estimated using the Kaplan-Meier product-limit method. A point estimate and a 95% confidence interval (CI) for the median PFS was computed for each randomization arm using the Brookmeyer & Crowley method. PD=Increase (= 20%) in sum of longest diameters from smallest value during study (including baseline).	Prior to study therapy, at 8 week intervals until progression occurs (maximum participant PFS of 71 weeks)	No
Primary	Participants With Disease Progression or Death for Exemestane Plus Dasatinib vs Exemestane Plus Placebo	PD is an increase (= 20%) in sum of longest diameters from smallest value during study (including baseline).	Prior to study therapy, at 8 week intervals until progression occurs. Maximum participant PFS of ____ months)	No
Secondary	Number of Participants With Best Overall Response	Complete response (CR) = Disappearance of all measurable and non-measurable lesions, and no new lesions; Partial response (PR) = Decrease =30% from baseline in sum of longest diameters (LD) of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions. SD = Disease re-assessment not qualifying as CR, PR or PD(=20% increase in sum of longest diameters from smallest value).	at 6 months	No
Secondary	Percentage of Participants With Clinical Benefit (CB) for Exemestane Plus Dasatinib Arm vs Exemestane Plus Placebo Arm at 6 Months	CB = participants whose best response is CR, PR, or stable disease(SD). CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease =30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions. SD = Disease re-assessment not qualifying as CR, PR or PD(=20% increase in sum of longest diameters from smallest value). Confidence interval computed by Clopper-Pearson method.	at 6 months	No
Secondary	Percentage of Participants With Response in Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms	Response= Proportion of response-evaluable participants whose best response is CR or PR. Confidence intervals was computed using the Clopper-Pearson method. CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease =30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.	Prior to study therapy, at 8 week intervals until progression occurs (maximum participant response was 39 weeks)	No
Secondary	Participants With Freedom-From-Progression (FFP) at 6 Months	FFP at month 6 is defined for the randomized participants who had the probability of neither progressing nor dying before 6 months.	at 6 months	No
Secondary	Time to Response for Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms	Time to response is defined as time from first dose of study therapy until measurement criteria are first met for PR or CR (whichever is recorded first). CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease =30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions.	Prior to study therapy, at 8 week intervals until CR or PR. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug, whichever is longer	No
Secondary	Duration of Response for Exemestane Plus Dasatinib Arm and Exemestane Plus Placebo Arms	Duration of response is defined as the time from date that measurement criteria are first met for PR or CR until first date of documented PD or death. CR = Disappearance of all measurable and non-measurable lesions, and no new lesions; PR = Decrease =30% from baseline in sum of longest diameters of all measurable lesions, with neither appearance of new lesions nor unequivocal progression of non-measurable lesions. PD=Increase (= 20%) in sum of longest diameters from smallest value during study (including baseline).	Prior to study therapy, at 8 week intervals. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug, whichever is longer.	No
Secondary	Changes in Participant-reported Pain Intensity in Participants With Bone Metastasis	Pain intensity evaluated by administration of the Brief Pain Inventory - Short Form (BPI-sf). The BPI-sf is a psychometrically-validated instrument which measures both pain severity and functional interference caused by pain using an 11-point numerical rating scale. Severity of pain at its "worst", "least" and "on average" in the last 24 hours, and "right now" (ie, at the time the questionnaire is being filled out) is recorded using anchors of "no pain" = "0" and "pain as bad as you can imagine" = "10".	Start of study, at treatment start, after 2, 4, and 8 weeks of therapy and every 8 weeks thereafter, at end-of-treatment. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug.	No
Secondary	Changes in Markers of Bone Lysis in Participants With Bone Metastasis	Assay for urinary N-telopeptide was used to evaluate Osteolytic activity.	Screening, Day 1, after week 2, 4, and week 8 and subsequently every 8 weeks, at end-of-treatment. Participants will remain on study (ie, last visit) until disease progression or 30 days after the last dose of study drug.	No
Secondary	Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs (as Per National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 3.0)	AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade (GR)1 = mild, GR 2 = moderate, GR 3=severe, GR 4=life threatening, GR 5=death.	From start of study drug therapy up to 30 days after the last dose. Median duration of therapy (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.	Yes
Secondary	Number of Participants With Grade 1-4 Hematology Abnormalities (as Per the NCI CTCAE, Version 3.0)	Abnormalities were graded per NCI-CTC, Version 3.0 criteria. Grade (GR)1 = mild, GR 2 = moderate, GR 3 = severe, GR 4 = life threatening. Normal ranges are provided by the Local Laboratory and may vary according to sex and age. Granulocytes, GR 1;	Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.	Yes
Secondary	Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Bilirubin, Calcium, Creatinine, and Albumin (as Per the NCI CTCAE, Version 3.0)	Grade (GR) 1 = mild, GR 2 = moderate, GR 3 = severe, GR 4 = life threatening). Normal ranges are provided by the Local Laboratory and may vary according to sex and age. Alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, GR 1: >ULN-2.5 x ULN (upper limit of normal), GR 2: >2.5-5.0 x ULN, GR 3: 5.0-20.0 x ULN; Low calcium, GR 1:	Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.	Yes
Secondary	Number of Participants With Grade 1-4 Serum Chemistry Abnormalities in Potassium, Magnesium, Sodium, Phosphorous, Uric Acid, and Bicarbonate (as Per the NCI CTCAE, Version 3.0)	Grade (GR)1= mild, GR2= moderate, GR3= severe, GR4= life threatening. Ranges are provided by the local laboratory and may vary according to sex and age. Phosphorous, GR1:	Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment. Median duration (on-study time) was 14.29 and 15.29 weeks for dasatinib and placebo groups, respectively.	Yes
Secondary	Number of Participants With Abnormalities in Vital Signs		Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment.	Yes
Secondary	Number of Participants With Abnormalities in Electrocardiograms		Data was collected prior treatment with the study drug, after week 2, 4, and week 8, every 8 weeks thereafter and at the end of the treatment.	Yes

External Links

•   BMS clinical trial educational resource
•   BMS Clinical Trial Information
•   For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm
•   Investigator Inquiry form